Mode
Text Size
Log in / Sign up
N/A N=439 Randomized Treatment

Screening to Augment Referral to Treatment- Project START

Alcohol Abuse · Tobacco Use Disorder · Marijuana Abuse · Substance-Related Disorders

Enrolled (actual)
439
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: Days Per Month of Primary Substance Use — 23.2; 23.7; 24.2; 19.3 days per month — p=<0.001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Motivational Interview (Behavioral); Treatment as Usual (Other)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Yale University
Primary completion
Jan 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Days Per Month of Primary Substance Use
23.2; 23.7; 24.2; 19.3; 19.7; 22.8 <0.001 sig
PRIMARY
Treatment Utilization
39; 39; 43; 106; 104; 108 0.810
SECONDARY
Rates of STDs
8; 4; 6; 135; 138; 152 0.465
SECONDARY
Mean Cost for Each Intervention
57.56; 21.07; 21.21

Summary

The investigators propose to use obstetric-gynecological clinics to conduct a randomized clinical trial that would compare two SBIRTS (Screening, Brief Intervention, Referral and Treatment), delivered either by a trained nurse or by computer, to usual care (a control condition). As part of this trial, the investigators will include outcomes that allow us to assess the cost effectiveness of these three conditions.

Eligibility Criteria

Inclusion Criteria

In order to participate, women must meet the following criteria:

  • Are non-pregnant and meet ASSIST criteria for at least moderate risk for alcohol (≥11) or drug (≥4) abuse or dependence (tobacco or illicit drugs, including cocaine, opiates, methamphetamine, marijuana or a prescription drug used in a medically inappropriate manner).
  • Are pregnant and meet ASSIST criteria for at least mild to moderate risk for alcohol (≥6) or drug (≥4) abuse or dependence (alcohol, tobacco, an illicit drug, or a prescription drug in a medically inappropriate manner). We define pregnant women who use alcohol or drugs at least monthly in the last 90 days as eligible because alcohol and many of the other substances (eg. tobacco) are teratogens and use in pregnancy would be consistent with a diagnosis of abuse ("recurrent use in situations in which it is physically hazardous"). This level of use in pregnancy also indicates a greater likelihood of problematic substance use.
  • Have used their primary substance at least once within the prior 28 days.
  • Are aged 18 or more. We include participants who are aged 18 or older because parents may not be available at screening to provide consent for non-pregnant participants and subjects may not wish to disclose drug or alcohol abuse to a parent.

Exclusion Criteria

Women are ineligible if they have any of the following criteria:

  • Are unable to speak English.
  • Are incarcerated or at risk of incarceration. The YNHH Women's Center provides care to incarcerated women. These individuals as well as those at risk of incarceration are excluded because incarceration precludes their ability to seek specialty drug or alcohol abuse treatment (a dependent measure).
  • Have a cognitive disorder that would impair their ability to provide informed consent or provide accurate information.
  • Require immediate hospitalization because of general medical needs or due to active suicidal or homicidal ideation or other behavioral health problems. We exclude individuals who are in need of immediate hospitalization because hospitalization will render it more difficult for them to immediately follow-up on a referral and because providers, rather than subjects, may be making the decision to initiate treatment. Hospitalization would also potentially force women who smoke to initiate treatment for tobacco addiction.
  • Are currently participating or have participated in drug abuse treatment, including self-help interventions (eg. 12 step facilitation, smoking cessation interventions), within the last 3 months prior to screening.
  • Are planning to relocate out of the area in the following 6 months. Women who relocate out of the area would be difficult to see for follow up assessments and it would be difficult to confirm treatment attendance in local treatment centers.
  • Have previously participated in this protocol or
  • Are unwilling to participate or accept randomization.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01539525). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search